The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk
Open accessAbstract
BACKGROUND AND OBJECTIVES: Hyperuricemia is associated with hypertension, inflammation, renal disease progression, and cardiovascular disease. However, no data are available regarding the effect of allopurinol in patients with chronic kidney disease. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a prospective, randomized trial of 113 patients with estimated GFR (eGFR) <60 ml/min. Patients were randomly assigned to treatment with allopurinol 100 mg/d (n = 57) or to continue the usual therapy (n = 56). Clinical, biochemical, and inflammatory parameters were measured at baseline and at 6, 12, and 24 months of treatment. The objectives of study were: (1) renal disease progression; (2) cardiovascular events; and (3) hospitalizations of any causes. RESULTS: Serum uric acid and C-reactive protein levels were significantly decreased in subjects treated with allopurinol. In the control group, eGFR decreased 3.3 +/- 1.2 ml/min per 1.73 m(2), and in the allopurinol group, eGFR increased 1.3 +/- 1.3 ml/min per 1.73 m(2) after 24 months. Allopurinol treatment slowed down renal disease progression independently of age, gender, diabetes, C-reactive protein, albuminuria, and renin-angiotensin system blockers use. After a mean follow-up time of 23.4 +/- 7.8 months, 22 patients suffered a cardiovascular event. Diabetes mellitus, previous coronary heart disease, and C-reactive protein levels increased cardiovascular risk. Allopurinol treatment reduces risk of cardiovascular events in 71% compared with standard therapy. CONCLUSIONS: Allopurinol decreases C-reactive protein and slows down the progression of renal disease in patients with chronic kidney disease. In addition, allopurinol reduces cardiovascular and hospitalization risk in these subjects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Uric Acid and Cardiovascular Risk
Feig, D. I., Kang, D.-H., & Johnson, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800885 · Cited by 2,440
Serum Uric Acid and Cardiovascular Mortality: The NHANES I Epidemiologic Follow-up Study, 1971-1992
Fang, J., & Alderman, M. H. (2000) · JAMA · doi:10.1001/jama.283.18.2404 · Cited by 1,513
Is There a Pathogenetic Role for Uric Acid in Hypertension and Cardiovascular and Renal Disease?
Johnson, R. J., Kang, D.-H., Feig, D., Kivlighn, S., Kanellis, J., Watanabe, S., Tuttle, K. R., Rodriguez-Iturbe, B., Herrera-Acosta, J., & Mazzali, M. (2003) · Hypertension · doi:10.1161/01.hyp.0000069700.62727.c5 · Cited by 1,361
Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study
Culleton, B. F., Larson, M. G., Kannel, W. B., & Levy, D. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-1-199907060-00003 · Cited by 1,282
Hyperuricemia induces endothelial dysfunction
Khosla, U. M., Zharikov, S., Finch, J. L., Nakagawa, T., Roncal, C., Mu, W., Krotova, K., Block, E. R., Prabhakar, S., & Johnson, R. J. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00273.x · Cited by 1,199
Feig, D. I., Soletsky, B., & Johnson, R. J. (2008) · JAMA · doi:10.1001/jama.300.8.924 · Cited by 914
Siu, Y.-P., Leung, K.-T., Tong, M. K.-H., & Kwan, T.-H. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.10.006 · Cited by 834
Uric acid and inflammatory markers
Ruggiero, C., Cherubini, A., Ble, A., Bos, A. J. G., Maggio, M., Dixit, V. D., Lauretani, F., Bandinelli, S., Senin, U., & Ferrucci, L. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi879 · Cited by 591
George, J., Carr, E., Davies, J., Belch, J. J. F., & Struthers, A. (2006) · Circulation · doi:10.1161/circulationaha.106.651117 · Cited by 569
Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure
Farquharson, C. A. J., Butler, R., Hill, A., Belch, J. J. F., & Struthers, A. D. (2002) · Circulation · doi:10.1161/01.cir.0000022140.61460.1d · Cited by 504
Cited by
The role of oxidative stress in the pathophysiology of hypertension
Rodrigo, R., González, J., & Paoletto, F. (2011) · Hypertension Research · doi:10.1038/hr.2010.264 · Cited by 436
Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease
Borghi, C., Agabiti-Rosei, E., Johnson, R. J., Kielstein, J. T., Lurbe, E., Mancia, G., Redon, J., Stack, A. G., & Tsioufis, K. P. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.07.006 · Cited by 435
Uric acid in metabolic syndrome: From an innocent bystander to a central player
Kanbay, M., Jensen, T., Solak, Y., Le, M., Roncal-Jimenez, C., Rivard, C., Lanaspa, M. A., Nakagawa, T., & Johnson, R. J. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.11.026 · Cited by 419
Ronco, C., Cicoira, M., & McCullough, P. A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.01.077 · Cited by 422
Oxidative stress in early diabetic nephropathy: fueling the fire
Singh, D. K., Winocour, P., & Farrington, K. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.212 · Cited by 353
Metadata
- Authors
- Goicoechea, M., de Vinuesa, S. G., Verdalles, U., Ruiz-Caro, C., Ampuero, J., Rincón, A., Arroyo, D., & Luño, J.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2010-08
- Volume
- 5
- Issue
- 8
- Pages
- 1388-1393
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2122983268
- Cited by
- 834
- References
- 17
- FWCI
- 44.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk. https://app.cochat.ai/papers/10.2215/cjn.01580210
- The paper
- Goicoechea, M., de Vinuesa, S. G., Verdalles, U., Ruiz-Caro, C., Ampuero, J., Rincón, A., Arroyo, D., & Luño, J. (2010). Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.01580210
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
